empty
 
 
ms
Search
Sokongan
Pembukaan akaun segera
Platform dagangan
Deposit/Pengeluaran
Search
Untuk Pedagang baru Untuk Pedagang Untuk Rakan Niaga Berehat sebentar Mengenai InstaSpot
ms
For Traders
Charts
#AUPH

#AUPH (Aurinia Pharmaceuticals Inc). Kadar pertukaran dan carta dalam talian.

#AMGN Kembali ke senarai instrumen #AZN

Pertukaran Matawang

Aurinia Pharmaceuticals Inc
15.78 USD
12 Dec 2025 22:59
Perubahan Harga (% chg)
$0.01
(0.06%)
Penutupan sebelum
Penutupan sebelum

Harga penutupan bagi hari sebelumnya.
$15.81
Buka
Buka

Harga Pembukaan.
$15.47
Paras Harga Tinggi
Paras Harga Tinggi

Harga tertinggi sepanjang hari terakhir dagangan.
$15.92
Paras Harga Rendah
Paras Harga Rendah

Harga terendah sepanjang hari terakhir dagangan.
$15.65
52 minggu di paras tinggi
52 minggu di paras tinggi

Paras harga tertinggi dalam 52 minggu terakhir
$15.92
52 minggu di paras rendah
52 minggu di paras rendah

Paras harga terendah dalam 52 minggu terakhir
$14.75
Muat turun arkib
Buy
15.78
Sell
15.78
Buka carta dalam paparan skrin penuh
Buy
15.78
Sell
15.78
Muat turun arkib
Buka carta dalam paparan skrin penuh

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a Canadian biotech company specializing in the production of drugs against autoimmune diseases.

Aurinia Pharmaceuticals Inc. maintains cooperation with Japanese companies, particularly Otsuka Pharmaceutical Co.

The company’s market cap currently stands at $1.067 billion. Aurinia reported revenues of $45.6 million last year with a net loss of $180.97 million.

Aurinia Pharmaceuticals Inc. stock and what affects it

The stock is traded on the NASDAQ exchange under the ticker name of AUPH. There is no information about upcoming dividend payments.

The stock is currently trading between $7.4 and $7.7. Over the past year, the share price has fluctuated from $6.29 to $33.97.

When trading this asset, you should pay attention to the following:

  • Any negative events and news will be detrimental to the company.
  • The company's earnings strongly depend on the results of new product trials.
  • It is not recommended to allocate more than 5% of your investment portfolio to this stock.
  • This is a high-risk stock with fairly large returns of over 30%.

Tidak boleh bertanya sekarang?
Tanya soalan anda di Ruangan bersembang.